Sign In
Buy IMAB
$4.63
+0 (+0%)
At Close: Apr 14, 2026
I-Mab: Why This Company Trades At A Third The Value Of Its Cash
04:59pm, Wednesday, 13'th Sep 2023
Chinese biotech company I-Mab faces challenges in attracting US capital due to lack of transparency and difficulty in valuing its pipeline. I-Mab has a late-stage pipeline with 20 assets and over $400
I-Mab Announces Upcoming Participation at September Conferences
08:00am, Tuesday, 05'th Sep 2023
ROCKVILLE, Md. and SHANGHAI , Sept.
I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates
06:00am, Thursday, 17'th Aug 2023
Significant progress made year-to-date on key clinical assets:‐ Uliledlimab (CD73 antibody): Encouraging early results were presented at ASCO 2023‐ Givastomig (Cl
I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023
08:00am, Tuesday, 08'th Aug 2023
ROCKVILLE, Md. and SHANGHAI , Aug. 8, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercializa
Theft in open court: How a fight over lifesaving drugs led to charges of brazen industrial espionage
09:40am, Tuesday, 27'th Jun 2023
A Chinese developer of cutting-edge cancer drugs has accused a chief competitor of stealing its trade secrets by posing as an expert witness in an arbitration hearing as a way of surreptitiously getti
I-Mab (IMAB) Q4 2022 Earnings Call Transcript
11:52am, Friday, 31'st Mar 2023
I-Mab (NASDAQ:IMAB ) Q4 2022 Earnings Conference Call March 31, 2023 8:15 AM ET Company Participants Tyler Ehler - Senior Director of Investor Relations Andrew Zhu - Acting Chief Executive Officer Ric
Here's Why IMab Sponsored ADR (IMAB) is Poised for a Turnaround After Losing 26.8% in 4 Weeks
11:18am, Wednesday, 05'th Oct 2022
IMab Sponsored ADR (IMAB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in
I-Mab: Another CD47 Inhibitor Biotech With Great Potential
02:30pm, Tuesday, 27'th Sep 2022
Clearance from China was received to initiate a phase 3 registrational study using Lemzoparlimab for high-risk MDS patients; trial initiation is expected in Q4 of 2022. Results from phase 2 studies us
I-Mab (IMAB) H1 2022 Earnings Call Transcript
02:01pm, Tuesday, 30'th Aug 2022
I-Mab (NASDAQ:IMAB ) H1 2022 Earnings Conference Call August 30, 2022 9:15 AM ET Company Participants Tyler Ehler – Senior Director of Investor Relations Jingwu Zang – Founder, Chairman and Acting
I-Mab (IMAB) Down After Partner AbbVie Revises Partnership Deal
02:18pm, Thursday, 18'th Aug 2022
I-Mab's (IMAB) partner AbbVie decides to stop early-stage development of an anti-CD47 antibody therapy targeting multiple cancer indications. IMAB intends to support the candidate's development.
I-Mab Valuation Offers A Biotech Investment Opportunity
05:27pm, Thursday, 23'rd Jun 2022
The biotech indices have fallen considerably. Many biotechs are trading with negative enterprise values despite unprecedented innovation in the biotech industry.
I-Mab to Hold Investor Call to Report Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab
08:00am, Thursday, 19'th May 2022
SHANGHAI and GAITHERSBURG, MD., May 19 , 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq" IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercializa
I-Mab (IMAB) CEO Management on Q4 2021 Results - Earnings Call Transcript
02:49pm, Tuesday, 29'th Mar 2022
I-Mab (IMAB) CEO Management on Q4 2021 Results - Earnings Call Transcript
I-Mab to Report Full Year 2021 Financial Results and Provide Corporate Update on March 29, 2022
08:00am, Friday, 18'th Mar 2022
SHANGHAI and GAITHERSBURG, MD, March 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercializ
U.S.-listed Chinese pharma stocks are on the rise
02:29pm, Wednesday, 16'th Mar 2022 Seeking Alpha
Despite recent regulatory hurdles, the U.S.-listed Chinese pharmaceutical companies have made a comeback in the morning hours on Wednesday.Notable gainers include I-Mab <>,…
